Literature DB >> 11783101

[A randomized clinical study of preoperative chemotherapy for esophageal carcinoma].

C Wang1, T Ding, L Chang.   

Abstract

OBJECTIVE: To evaluate the effect of preoperative chemotherapy on the prognosis of stage II or III patients with esophageal carcinoma.
METHODS: From February 1991 to June 1994, 50 patients with stage II, III esophageal carcinoma were treated with preoperative combination (CDDP) chemotherapy and compared with 50 patients received operation alone.
RESULTS: The 5-year survival rate of the operation group and preoperative chemotherapy group was 32% and 46%, respectively. The difference was statistically significant.
CONCLUSION: Preoperative chemotherapy improves survival of surgically treated esophageal cancer patients.

Entities:  

Mesh:

Year:  2001        PMID: 11783101

Source DB:  PubMed          Journal:  Zhonghua Zhong Liu Za Zhi        ISSN: 0253-3766


  6 in total

Review 1.  Neoadjuvant treatment of esophageal cancer.

Authors:  Nicholas P Campbell; Victoria M Villaflor
Journal:  World J Gastroenterol       Date:  2010-08-14       Impact factor: 5.742

Review 2.  Current management of esophageal cancer.

Authors:  Simon Law; John Wong
Journal:  J Gastrointest Surg       Date:  2005-02       Impact factor: 3.452

Review 3.  The frontline of esophageal cancer treatment: questions to be asked and answered.

Authors:  Cheng-Che Tu; Po-Kuei Hsu
Journal:  Ann Transl Med       Date:  2018-02

Review 4.  Preoperative chemotherapy for resectable thoracic esophageal cancer.

Authors:  Biniam Kidane; Shaun Coughlin; Kelly Vogt; Richard Malthaner
Journal:  Cochrane Database Syst Rev       Date:  2015-05-19

5.  EphA5 Silencing Increases the Radiosensitivity of ESCC Cells Through ATM-Dependent Pathway.

Authors:  Rui Zhang; Dan Han; Lu Li; Wenguang Luo; Jing Liu; Liting Qian
Journal:  Cancer Manag Res       Date:  2020-10-02       Impact factor: 3.989

Review 6.  Undervalued criteria in the evaluation of multimodal trials for upper GI cancers.

Authors:  Björn L D M Brücher; Masaki Kitajima; Jörg Rüdiger Siewert
Journal:  Cancer Invest       Date:  2014-09-24       Impact factor: 2.176

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.